The therapeutic potential of CNB-001 is supported by its ability to reduce behavioral impairments, oxidative stress, and mitochondrial deficits and by enhancing expressions of TH, DAT, and VMAT2 in animal model of PD. Here, SLC18A2 is linked to Parkinson disease.